Not every "Certificate of Analysis" answers the same question. Here's what's actually tested at each tier of the peptide supply chain, and why purity alone doesn't tell you a product is safe to inject.
A peptide vial can carry a document that looks official — a lab letterhead, a purity number, a chromatogram — without telling you anything about sterility, contamination, or whether the material inside matches the label. The difference isn't always visible on the page. It's in what was tested, and what wasn't.
Below is a real, side-by-side comparison of the three tiers of documentation a peptide buyer is likely to encounter, built from actual document structures at each tier.
No named lab, no disclosed method, no lot traceability. Often just a percentage on a page with no way to verify who tested it or how.
A named lab, a stated method (HPLC-UV, LC-MS), identity and purity results. Explicitly labeled "research use only — not for human use," and typically stops at identity and purity.
Full release panel — identity, purity, impurities, residual solvents, heavy metals, water content, endotoxin, sterility — reviewed by QC and approved by QA, then released by a licensed pharmacist to a named patient.
| Attribute | Grey Market | Research-Market (RUO) | GMP + Pharmacy Release |
|---|---|---|---|
| Named testing laboratory | Rarely | Yes | Yes |
| Method disclosed | No | Yes (HPLC-UV, LC-MS) | Yes, per attribute |
| Identity confirmation | Unverified | Mass spec | Mass spec |
| Purity (HPLC) | Claimed only | Reported | Reported vs. reference standard |
| Net peptide content | No | Yes | Yes, plus mass balance calc |
| Related substances / impurity profile | No | No | Yes, each impurity itemized |
| Residual solvents (GC) | No | No | Yes |
| Elemental impurities / heavy metals (ICP-MS) | No | No | Yes |
| Water content (Karl Fischer) | No | No | Yes |
| Bacterial endotoxin | No | No | Yes |
| Microbiological / sterility testing | No | No | Yes |
| QC review + QA approval chain | No | Analyst sign-off only | Full QC/QA sign-off |
| Manufacturing / re-test dates | No | Sometimes | Yes |
| Pharmacist release review | No | No | Yes |
| Dispensed to named patient by prescription | No | No | Yes |
Comparison reflects typical document structure at each tier, illustrated using a genericized research-market CoA and a genericized GMP/503A release CoA template. Actual attributes, methods, and limits vary by product and by pharmacy.
The most common gap between a research-market CoA and a full release CoA isn't dishonesty — it's scope. HPLC purity testing measures how much of the sample is the target peptide relative to other UV-absorbing compounds. It was never designed to detect bacterial endotoxin, heavy metals, or residual solvents, because those don't absorb UV light the same way. A sample can report 99%+ purity by HPLC and still contain contamination that purity testing simply cannot see.
That's the reason a full release panel tests those attributes separately, with separate methods — ICP-MS for heavy metals, a bacterial endotoxin assay, and dedicated microbiological testing for sterility. Each answers a different question. None of them substitute for the others.
of samples across 6,441 independently tested peptide products showed measurable endotoxin contamination, in an analysis spanning 14 common compounds.
of the same sample set failed to meet basic quality criteria, depending on which regulatory standard was applied — 503A-equivalent or FDA-approved-drug-equivalent.
of gray-market samples tested for endotoxin in two independent testing programs showed quantifiable contamination above trace levels.
Figures reflect independent third-party testing data published in 2026, cited for educational context. They describe patterns across the unregulated market broadly, not any specific vendor or product.
If the answer to most of these is no, what you're holding is a purity claim — not a safety profile.
The complete Know Your Vial library includes annotated example documents at each tier.
Visit Know Your Vial →